You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 17, 2024

GVOKE HYPOPEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Gvoke Hypopen patents expire, and when can generic versions of Gvoke Hypopen launch?

Gvoke Hypopen is a drug marketed by Xeris and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-four patent family members in fifteen countries.

The generic ingredient in GVOKE HYPOPEN is glucagon. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the glucagon profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Gvoke Hypopen

A generic version of GVOKE HYPOPEN was approved as glucagon by FRESENIUS KABI USA on May 8th, 2015.

  Sign Up

US Patents and Regulatory Information for GVOKE HYPOPEN

GVOKE HYPOPEN is protected by two US patents.

Patents protecting GVOKE HYPOPEN


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF SEVERE HYPOGLYCEMIA

Methods for producing stable therapeutic formulations in aprotic polar solvents
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF SEVERE HYPOGLYCEMIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xeris GVOKE HYPOPEN glucagon SOLUTION;SUBCUTANEOUS 212097-003 Sep 10, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Xeris GVOKE HYPOPEN glucagon SOLUTION;SUBCUTANEOUS 212097-004 Sep 10, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Xeris GVOKE HYPOPEN glucagon SOLUTION;SUBCUTANEOUS 212097-003 Sep 10, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Xeris GVOKE HYPOPEN glucagon SOLUTION;SUBCUTANEOUS 212097-004 Sep 10, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for GVOKE HYPOPEN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Tetris Pharma B.V Ogluo glucagon EMEA/H/C/005391
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Authorised no no no 2021-02-11
Eli Lilly Nederland B.V. Baqsimi glucagon EMEA/H/C/003848
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Authorised no no no 2019-12-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for GVOKE HYPOPEN

See the table below for patents covering GVOKE HYPOPEN around the world.

Country Patent Number Title Estimated Expiration
South Korea 20240056643 양극성 용매에서 안정한 치료 제형들의 제조방법 (METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS) ⤷  Sign Up
China 108135980 在非质子极性溶剂中制备稳定的胰高血糖素治疗制剂的方法 (METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS) ⤷  Sign Up
Brazil 112018005800 métodos para produzir formulações terapêuticas estáveis em solventes apolares apróticos ⤷  Sign Up
South Africa 201904146 METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS ⤷  Sign Up
Australia 2016326749 Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents ⤷  Sign Up
Hong Kong 1250644 在非質子極性溶劑中製造穩定的治療性胰高血糖素之製劑的方法 (METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.